Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Current Leases (2021 - 2025)

Vivos Therapeutics' Current Leases history spans 5 years, with the latest figure at $55000.0 for Q4 2025.

  • Quarterly results put Current Leases at $55000.0 for Q4 2025, down 88.47% from a year ago — trailing twelve months through Dec 2025 was $55000.0 (down 88.47% YoY), and the annual figure for FY2025 was $55000.0, down 88.47%.
  • Current Leases for Q4 2025 was $55000.0 at Vivos Therapeutics, roughly flat from $55000.0 in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $654000.0 in Q2 2025 to a low of $55000.0 in Q3 2025.
  • The 5-year median for Current Leases is $447000.0 (2023), against an average of $391235.3.
  • The sharpest move saw Current Leases soared 481.94% in 2022, then tumbled 88.66% in 2025.
  • Year by year, Current Leases stood at $72000.0 in 2021, then soared by 481.94% to $419000.0 in 2022, then rose by 13.13% to $474000.0 in 2023, then grew by 0.63% to $477000.0 in 2024, then tumbled by 88.47% to $55000.0 in 2025.
  • According to Business Quant data, Current Leases over the past three periods came in at $55000.0, $55000.0, and $654000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.